Suchitra Sundaram, MD, reviews new data on CLL treatments presented at ASH 2024, highlighting exciting possibilities for future patient care. She recounts the case of a 75-year-old man with worsening CLL symptoms, unmutated IgVH, trisomy 12, and wild-type TP53 who expressed interest in a time-limited treatment. Dr Sundaram then discusses relevant findings from the CLL14 trial, which showed that undetectable minimal residual disease (MRD) at the end of venetoclax-obinutuzumab therapy predicted better progression-free survival, as well as a phase 2 trial exploring MRD-adapted treatment durations.
Additionally, the AMPLIFY phase 3 trial demonstrated that combining acalabrutinib and venetoclax significantly improved progression-free survival compared with chemoimmunotherapy. This all-oral regimen offers a promising, well-tolerated, time-limited treatment option.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASH 2024: The Clinical Impact of New CLL Data - Medscape - Dec 26, 2024.
Comments